Savient Pharmaceuticals (SVNT)
Savient Pharmaceuticals Revenue Growth: 174.0%
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
SVNT Revenue Growth Rankings
| Overall | 98th percentile | 72 of 4363 |
| Sector | 94th percentile | 24 of 457 in Healthcare |
| Industry | 84th percentile | 19 of 126 in Biotechnology |
SVNT Revenue Growth Range, Past 5 Years
| Minimum | -88.72% | Jun 2008 |
| Maximum | 286.5% | Dec 2011 |
| Average | 24.63% |
About Revenue Growth
Revenue growth illustrates sales increases/decreases over time. It is used to measure how fast a business is expanding. More valuable than a snapshot of revenue, revenue growth helps investors identify trends in order to gauge revenue growth over time.
If a company generated $75 billion in revenue during 2008 and $100 billion in revenue during 2009, the company experienced roughly a ($100 billion/$75 billion)-1 = %33 increase in revenue.
Learn More
You may also be interested in these SVNT related companies
SVNT News
Savient Pharma (SVNT) Moves Higher with Volatility; Bumps Up Against Key Resistance Point
May 25, 2:16PM Street Insider
May 25, 2:16PM Street Insider
@AvantNoir I'll wait till $SVNT shows a little green 1st, then stop it at the low of the day before.
about 11 days ago by Urbane_Gorilla
about 11 days ago by Urbane_Gorilla
Unusual 11 Mid-Day Movers 05/17: (MEG) (GALE) (XG) Higher; (WFR) (SVNT) (DANG) Lower
May 17, 1:06PM Street Insider
May 17, 1:06PM Street Insider
Savient Pharmaceuticals Completes Financing and Debt Restructuring Transactions
May 09, 3:32PM Benzinga
May 09, 3:32PM Benzinga
Listen to $SVNT Q1 2012 earnings call - live at 09:00 AM, ondemand after - http://stks.co/3jw2
about 23 days ago by earningscast
about 23 days ago by earningscast
Savient Pharmaceuticals Enters Into Definitive Financing and Debt Restructuring Agreements
May 08, 6:41AM Benzinga
May 08, 6:41AM Benzinga
Savient (SVNT) Shares Hit as BioCryst (BCRX) Gets FDA Guidance for Gout Treatment Approval
May 07, 12:32PM Street Insider
May 07, 12:32PM Street Insider
Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
May 03, 4:05PM PR Newswire
May 03, 4:05PM PR Newswire
Unusual 11 Mid-Day Movers 05/02: (SMSC) (CHRS) (WWWW) Higher; (END) (UBNT) (CEVA) Lower
May 02, 1:24PM Street Insider
May 02, 1:24PM Street Insider
Savient Pharma (SVNT) Shares Nosedive as Co. Served with Credit Derivative Action
May 01, 1:52PM Street Insider
May 01, 1:52PM Street Insider
@jimo66 You have some interesting plays. Like $CBOU the best. Curious as to y $SVNT is going higher.
about 38 days ago by schenek
about 38 days ago by schenek
$SVNT moving above the swing high. Now maybe the shorts will start covering.
about 42 days ago by Lonetree
about 42 days ago by Lonetree
Option Alert: Savient Pharmaceuticals January 2013 2.5 Call; Block Trade, 2,000 Contracts
Apr 11, 10:57AM Benzinga
Apr 11, 10:57AM Benzinga
Savient Pharmaceuticals to Present at the Imperial Capital Healthcare Investor Forum
Apr 03, 4:05PM PR Newswire
Apr 03, 4:05PM PR Newswire
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| SVNT | 0.7243 | -0.03 | -4.53% | 51.98M |
| SVN | 9.68 | -0.04 | -0.41% | 482.84M |
| SVM | 6.20 | +0.14 | +2.31% | 1.034B |
| SVBI | 3.21 | +1.02 | +46.58% | 32.32M |
| SVA | 1.85 | +0.03 | +1.65% | 101.08M |
| SUTR | 0.85 | -0.07 | -7.62% | 34.30M |
| SUSS | 28.79 | -0.46 | -1.57% | 612.79M |
| STLY | 3.90 | -0.05 | -1.20% | 56.63M |
| STLD | 10.32 | -0.22 | -2.09% | 2.309B |
| STL | 9.10 | -0.01 | -0.11% | 281.37M |
